Researchers at The University of Western Australia and King Edward Memorial Hospital have teamed up with SpeeDx to commercialise a new low-cost test to identify women at risk of premature...
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets. SpeeDx collaborates with key researchers and organizations around the globe...
SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials and new product development. "We welcome this extension of the utility...
PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the busy 2019 flu season. The test utilises market-leading multiplex technology...
SpeeDx announced further series A funding received by new investor partners, Northpond Ventures, LP – a U.S.-based, formative stage venture capital fund with a strong science and technology driven portfolio....
ResistancePlus® MG will be the first test available through Cepheid's FleXible cartridge program. This partnership will increase access for clinicians and support Resistance Guided Therapy in the management of Mycoplasma...
New distribution partners, Al Zahrawi Medical Supplies LLC, will distribute SpeeDx ResistancePlus® and PlexPCR® tests across UAE, Saudi Arabia, Oman, Bahrain, and Qatar. “Al Zahrawi Medical are the leading medical and...
SpeeDx announced submission of the PlexPCR® RespiVirus test to the Therapeutic Goods Administration (TGA), with anticipated clearance in time for the Australian 2019 flu season. The test utilises market-leading PlexPCR®...
SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae, and sequences in the gyrA...
SpeeDx have signed of a further four distribution partners, in preparation to strengthen representation across Europe. Axonlab (Germany, Benelux and Switzerland), Vircell (Spain), Diamedica (Estonia, Latvia, and Lithuania) and Biomedica...